ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
35/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 7 wins, 5 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinADPT / S&P 54.54% / 15.20% |
WinADPT / S&P 50.13% / 15.00% |
LoseADPT / S&P -49.38% / 50.40% |
| 2026-Q11/3 |
LoseADPT / S&P -14.53% / -4.33% |
WinADPT / S&P 55.87% / 11.30% |
LoseADPT / S&P -65.26% / 27.70% |
| 2025-Q42/3 |
WinADPT / S&P 8.56% / 2.65% |
WinADPT / S&P 54.77% / 9.00% |
LoseADPT / S&P -62.96% / 13.40% |
| 2025-Q32/3 |
WinADPT / S&P 28.41% / 8.12% |
WinADPT / S&P 42.57% / 4.61% |
LoseADPT / S&P -60.45% / 13.45% |
| 2025-Q22/3 |
WinADPT / S&P 56.80% / 10.94% |
WinADPT / S&P 21.60% / 4.83% |
LoseADPT / S&P -44.90% / 10.63% |
| 2025-Q12/3 |
WinADPT / S&P 23.94% / -4.27% |
WinADPT / S&P 8.61% / 4.98% |
LoseADPT / S&P -36.24% / 10.57% |
| 2024-Q41/3 |
WinADPT / S&P 17.09% / 2.41% |
LoseADPT / S&P 5.10% / 5.25% |
LoseADPT / S&P -30.77% / 6.15% |
| 2024-Q31/3 |
WinADPT / S&P 41.44% / 5.89% |
LoseADPT / S&P -1.34% / 5.89% |
LoseADPT / S&P -1.47% / 6.11% |
| 2024-Q22/3 |
WinADPT / S&P 12.77% / 4.28% |
LoseADPT / S&P -10.99% / 5.38% |
WinADPT / S&P 10.53% / 5.12% |
| 2024-Q11/3 |
LoseADPT / S&P -34.49% / 10.56% |
LoseADPT / S&P -5.33% / 5.71% |
WinADPT / S&P 8.76% / 5.59% |
| 2023-Q41/3 |
LoseADPT / S&P -10.09% / 11.69% |
LoseADPT / S&P -8.11% / 6.81% |
WinADPT / S&P 10.64% / 7.78% |
| 2023-Q30/3 |
LoseADPT / S&P -18.78% / -3.27% |
LoseADPT / S&P 6.93% / 7.52% |
LoseADPT / S&P -13.38% / -5.03% |
| 2023-Q21/3 |
LoseADPT / S&P -24.01% / 8.74% |
WinADPT / S&P 18.74% / 9.50% |
LoseADPT / S&P -19.39% / -8.57% |
| 2023-Q12/3 |
WinADPT / S&P 15.58% / 7.50% |
WinADPT / S&P 19.29% / 10.77% |
LoseADPT / S&P -15.95% / -15.69% |
| 2022-Q41/3 |
LoseADPT / S&P 7.30% / 7.56% |
WinADPT / S&P 20.06% / 11.88% |
LoseADPT / S&P ADPT unavailable / -17.99% |
| 2022-Q31/3 |
LoseADPT / S&P -11.99% / -4.88% |
WinADPT / S&P 14.63% / 13.47% |
LoseADPT / S&P ADPT unavailable / -1.41% |
| 2022-Q21/3 |
LoseADPT / S&P -41.71% / -16.10% |
WinADPT / S&P 19.67% / 13.71% |
LoseADPT / S&P ADPT unavailable / 11.04% |
| 2022-Q11/3 |
LoseADPT / S&P -50.53% / -4.60% |
WinADPT / S&P 33.31% / 15.97% |
LoseADPT / S&P ADPT unavailable / 42.23% |
| 2021-Q41/3 |
LoseADPT / S&P -17.45% / 11.03% |
WinADPT / S&P 56.88% / 15.00% |
LoseADPT / S&P ADPT unavailable / 96.40% |
| 2021-Q31/3 |
LoseADPT / S&P -16.81% / 0.58% |
WinADPT / S&P 58.65% / 10.77% |
LoseADPT / S&P ADPT unavailable / 69.42% |
| 2021-Q21/3 |
LoseADPT / S&P 1.49% / 8.55% |
WinADPT / S&P 44.77% / 6.58% |
LoseADPT / S&P ADPT unavailable / 51.81% |
| 2021-Q11/3 |
LoseADPT / S&P -31.91% / 6.17% |
WinADPT / S&P 24.22% / -1.06% |
LoseADPT / S&P ADPT unavailable / 7.39% |
| 2020-Q42/3 |
WinADPT / S&P 21.59% / 12.15% |
WinADPT / S&P 15.65% / -3.72% |
LoseADPT / S&P ADPT unavailable / -33.42% |
| 2020-Q31/3 |
LoseADPT / S&P 0.52% / 8.93% |
WinADPT / S&P 18.39% / -2.04% |
LoseADPT / S&P ADPT unavailable / -27.10% |
| 2020-Q22/3 |
WinADPT / S&P 74.15% / 20.54% |
WinADPT / S&P 33.22% / -0.46% |
LoseADPT / S&P ADPT unavailable / -27.11% |
| 2020-Q12/3 |
WinADPT / S&P -7.15% / -19.60% |
WinADPT / S&P 59.20% / 3.47% |
LoseADPT / S&P ADPT unavailable / -14.75% |
| 2019-Q40/3 |
LoseADPT / S&P -3.17% / 9.07% |
LoseADPT / S&P ADPT unavailable / 5.36% |
LoseADPT / S&P ADPT unavailable / 2.99% |
| 2019-Q30/3 |
LoseADPT / S&P -36.02% / 1.70% |
LoseADPT / S&P ADPT unavailable / 5.02% |
LoseADPT / S&P ADPT unavailable / 0.21% |
| 2019-Q20/3 |
LoseADPT / S&P ADPT unavailable / 4.30% |
LoseADPT / S&P ADPT unavailable / 6.64% |
LoseADPT / S&P ADPT unavailable / 8.65% |
| 2019-Q10/3 |
LoseADPT / S&P ADPT unavailable / 13.65% |
LoseADPT / S&P ADPT unavailable / 8.12% |
LoseADPT / S&P ADPT unavailable / 14.29% |
| 2018-Q40/3 |
LoseADPT / S&P ADPT unavailable / -13.52% |
LoseADPT / S&P ADPT unavailable / 9.05% |
LoseADPT / S&P ADPT unavailable / 18.23% |
| 2018-Q30/3 |
LoseADPT / S&P ADPT unavailable / 7.71% |
LoseADPT / S&P ADPT unavailable / 10.21% |
LoseADPT / S&P ADPT unavailable / 19.06% |
| 2018-Q20/3 |
LoseADPT / S&P ADPT unavailable / 3.43% |
LoseADPT / S&P ADPT unavailable / 9.03% |
LoseADPT / S&P ADPT unavailable / 14.46% |
| 2018-Q10/3 |
LoseADPT / S&P ADPT unavailable / -0.76% |
LoseADPT / S&P ADPT unavailable / 7.68% |
LoseADPT / S&P ADPT unavailable / 12.46% |
| 2017-Q40/3 |
LoseADPT / S&P ADPT unavailable / 6.64% |
LoseADPT / S&P ADPT unavailable / 7.03% |
LoseADPT / S&P ADPT unavailable / 13.82% |
| 2017-Q30/3 |
LoseADPT / S&P ADPT unavailable / 4.48% |
LoseADPT / S&P ADPT unavailable / 5.68% |
LoseADPT / S&P ADPT unavailable / 17.57% |
| 2017-Q20/3 |
LoseADPT / S&P ADPT unavailable / 3.09% |
LoseADPT / S&P ADPT unavailable / 4.83% |
LoseADPT / S&P ADPT unavailable / 17.74% |
| 2017-Q10/3 |
LoseADPT / S&P ADPT unavailable / 6.07% |
LoseADPT / S&P ADPT unavailable / 3.67% |
LoseADPT / S&P ADPT unavailable / 13.32% |
| 2016-Q40/3 |
LoseADPT / S&P ADPT unavailable / 3.82% |
LoseADPT / S&P ADPT unavailable / 2.09% |
LoseADPT / S&P ADPT unavailable / 7.05% |
| 2016-Q30/3 |
LoseADPT / S&P ADPT unavailable / 3.85% |
LoseADPT / S&P ADPT unavailable / 0.20% |
LoseADPT / S&P ADPT unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ADPT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 100.61% | 20.78% |
| Annualized return | 100.61% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ADPT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -30.15% | 83.14% |
| Annualized return | -6.92% | 12.86% |
10Y · 2019-06-27 to 2026-08-27
| Metric | ADPT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -34.39% | 319.30% |
| Annualized return | -4.13% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |